

Peter Quehenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2453242/publications.pdf>

Version: 2024-02-01

57
papers

1,215
citations

430874

18
h-index

414414

32
g-index

60
all docs

60
docs citations

60
times ranked

1893
citing authors

#	ARTICLE	IF	CITATIONS
1	Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. <i>Clinical Chemistry</i> , 2020, 66, 1405-1413.	3.2	122
2	High Concentrations of Soluble P-Selectin Are Associated with Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. <i>Clinical Chemistry</i> , 2007, 53, 1235-1243.	3.2	110
3	Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1819-1822.	3.8	91
4	Emicizumab for the treatment of acquired hemophilia A. <i>Blood</i> , 2021, 137, 410-419.	1.4	83
5	Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. <i>Thrombosis Research</i> , 2014, 134, 918-923.	1.7	66
6	Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). <i>Blood</i> , 2015, 125, 3477-3483.	1.4	63
7	Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. <i>Thrombosis Research</i> , 2016, 137, 196-201.	1.7	48
8	Lupus-anticoagulant testing at NOAC trough levels. <i>Thrombosis and Haemostasis</i> , 2016, 116, 235-240.	3.4	47
9	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39
10	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	3.9	36
11	FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. <i>Blood</i> , 2016, 128, 293-296.	1.4	34
12	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-dimer analysis: A prospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1348-1356.	3.8	34
13	A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. <i>EBioMedicine</i> , 2021, 67, 103348.	6.1	34
14	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
15	Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. <i>Annals of Hematology</i> , 2017, 96, 489-495.	1.8	21
16	Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications. <i>Annals of Hematology</i> , 2017, 96, 1023-1031.	1.8	21
17	Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. <i>Clinical and Experimental Medicine</i> , 2018, 18, 325-336.	3.6	21
18	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	3.9	21

#	ARTICLE	IF	CITATIONS
19	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. <i>BMC Medicine</i> , 2017, 15, 54.	5.5	20
20	Dynamic reference intervals for coagulation parameters from infancy to adolescence. <i>Clinica Chimica Acta</i> , 2018, 482, 124-135.	1.1	17
21	Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit®) Tj ETQq1 1 0,784314 rgBT /Ove	1.7	16
22	Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction. <i>Cardiovascular Research</i> , 2022, 118, 2006-2017.	3.8	16
23	The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial. <i>Haematologica</i> , 2022, 107, 2121-2132.	3.5	16
24	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. <i>Thrombosis Research</i> , 2021, 207, 126-130.	1.7	15
25	The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. <i>Thrombosis Research</i> , 2007, 120, 295-302.	1.7	14
26	Evaluating the analytical performance of five new coagulation assays for the measurement of prothrombin time and activated thromboplastin time. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 645-654.	1.3	13
27	Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1081-1086.	3.8	13
28	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
29	Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 249-255.	1.2	11
30	Evaluation of between-, within- and day-to-day variation of coagulation measured by rotational thrombelastometry (ROTEM). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 651-657.	1.2	10
31	Prevalence and Clinical Impact of Reduced Coagulation Factor XII Activity in Patients Receiving Extracorporeal Membrane Oxygenation. <i>Critical Care Medicine</i> , 2021, 49, e1206-e1211.	0.9	10
32	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	2.5	10
33	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , 2020, 14, 1083-1092.	4.2	9
34	Homozygous antithrombin deficiency type II causing neonatal thrombosis. <i>Thrombosis Research</i> , 2017, 158, 134-137.	1.7	8
35	Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D-dimer and thrombin time. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 637-644.	1.3	8
36	Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases. <i>Blood</i> , 2018, 132, 2476-2476.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	3.4	7
38	The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. <i>Blood Advances</i> , 2022, 6, 5467-5476.	5.2	6
39	Interference in specialized coagulation assays affecting the protein C pathway: Effects of marked haemolysis, hyperbilirubinaemia and lipaemia on chromogenic and clotting tests on two coagulation platforms. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 404-411.	1.3	5
40	Limitations of a calibrated, quantitative APC assay under routine conditions. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 318-323.	1.3	5
41	The Effect of 3.2% and 3.8% Sodium Citrate on Specialized Coagulation Tests. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 992-997.	2.5	3
42	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy. <i>Pharmaceutics</i> , 2022, 14, 662.	4.5	3
43	Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.. <i>Blood</i> , 2008, 112, 2291-2291.	1.4	2
44	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Blood</i> , 2008, 112, 3824-3824.	1.4	2
45	Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study. <i>Biochimica Medica</i> , 2017, 27, 030705.	2.7	2
46	Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24294.	2.1	2
47	Assay validity of point-of-care platelet function tests in thrombocytopenic blood samples. <i>Biochimica Medica</i> , 2022, 32, 291-301.	2.7	2
48	A model comparing how rapidly transfusion of solvent detergent plasma restores clotting factors versus infusion of albumin-saline. <i>Transfusion and Apheresis Science</i> , 2015, 53, 360-367.	1.0	1
49	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.9	1
50	Anticoagulation strategy in a patient on the HeartMate III® left ventricular assist device with acquired von Willebrand syndrome and recurring gastrointestinal bleeding episodes: sometimes less is more. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 796-798.	1.4	1
51	Immature cell fractions after cessation of chronic P2Y ₁₂ -inhibition in patients with coronary artery diseases. <i>Platelets</i> , 2021, 32, 815-820.	2.3	1
52	Delayed Plasma Clot Lysis in Adult Patients with Primary Immune Thrombocytopenia (ITP). <i>Blood</i> , 2021, 138, 3162-3162.	1.4	1
53	Lupus anticoagulant test persistence over time and its associations with future thrombotic events. <i>Blood Advances</i> , 2022, , .	5.2	1
54	Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent. <i>Blood</i> , 2013, 122, 3602-3602.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a. Blood, 2019, 134, 1135-1135.	1.4	0
56	Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia. , 2019, 39, .		0
57	Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant. Blood, 2021, 138, 290-290.	1.4	0